| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-Aminoadenosine targets adenosine kinase, serving as either an inhibitor or substrate of this enzyme. The compound also inhibits DNA polymerase and RNA polymerase activities. By inhibiting these polymerases, the compound interferes with DNA and RNA synthesis, leading to inhibition of cancer cell growth.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, 2-Aminoadenosine inhibits DNA polymerase and RNA polymerase activities. The compound serves as a substrate for adenosine kinase from M. tuberculosis. These activities demonstrate the compound's direct effects on nucleic acid synthesis enzymes and adenosine metabolism.
|
| ln Vivo |
In cell-based assays, 2-Aminoadenosine has been shown to inhibit the growth of certain cancer cells in vitro. The compound's mechanism of action involves inhibition of DNA and RNA synthesis through polymerase inhibition. The compound is used to study adenosine receptor activity and has potential applications in drug development, particularly in neurological disorders and cancer therapy.
|
| Enzyme Assay |
The cell-free assay for DNA polymerase inhibition involves measuring the incorporation of radiolabeled nucleotides into DNA in the presence of the compound. The reaction contains purified DNA polymerase, template DNA, dNTPs, and the inhibitor at various concentrations. The RNA polymerase inhibition assay is performed similarly using RNA polymerase and NTPs. The IC50 values are determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for anti-cancer activity involve culturing cancer cell lines and treating them with 2-Aminoadenosine at concentrations ranging from 0.1 to 100 μM. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CCK-8 assays. The effect on DNA and RNA synthesis can be measured by incorporation of labeled precursors. The compound's effects on adenosine receptor signaling can be assessed in appropriate cell models.
|
| Animal Protocol |
There is no established animal experimental protocol for 2-Aminoadenosine specifically. As an adenosine analog with anti-cancer activity, the compound could potentially be evaluated in animal models of cancer. Typical protocols for nucleoside analogs involve administration to tumor-bearing mice via intraperitoneal or intravenous routes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Aminoadenosine have not been extensively reported. As a small molecule with molecular weight of 282.26 g/mol, the compound would be expected to have reasonable bioavailability and tissue penetration. The presence of the additional amino group may affect the compound's metabolism and distribution. Further pharmacokinetic studies would be required.
|
| Toxicity/Toxicokinetics |
Toxicity data for 2-Aminoadenosine are not well documented. As a nucleoside analog that inhibits DNA and RNA synthesis, the compound may have toxicity toward rapidly dividing cells, which could translate to bone marrow suppression and gastrointestinal toxicity. Standard toxicity studies would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
2-Aminoadenosine is a purine nucleoside.
2-Aminoadenosine is a research compound used to study adenosine kinase activity, adenosine receptor signaling, and nucleic acid synthesis inhibition. The compound inhibits DNA polymerase and RNA polymerase activities and has been shown to inhibit the growth of certain cancer cells in vitro. It has potential applications in drug development for neurological disorders and cancer therapy. It is not an approved pharmaceutical and has no clinical trial history. This product is intended for research use only. |
| Molecular Formula |
C10H14N6O4
|
|---|---|
| Molecular Weight |
282.26
|
| Exact Mass |
282.107
|
| CAS # |
2096-10-8
|
| PubChem CID |
72200
|
| Appearance |
White to off-white solid powder
|
| Density |
2.3±0.1 g/cm3
|
| Boiling Point |
798.5±70.0 °C at 760 mmHg
|
| Melting Point |
241-243°C (dec.)
|
| Flash Point |
436.7±35.7 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.986
|
| LogP |
-1.08
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
363
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)N
|
| InChi Key |
ZDTFMPXQUSBYRL-UUOKFMHZSA-N
|
| InChi Code |
InChI=1S/C10H14N6O4/c11-7-4-8(15-10(12)14-7)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H4,11,12,14,15)/t3-,5-,6-,9-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-(2,6-diaminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~354.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5428 mL | 17.7142 mL | 35.4283 mL | |
| 5 mM | 0.7086 mL | 3.5428 mL | 7.0857 mL | |
| 10 mM | 0.3543 mL | 1.7714 mL | 3.5428 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
